0001104659-22-076722.txt : 20220701
0001104659-22-076722.hdr.sgml : 20220701
20220701132320
ACCESSION NUMBER: 0001104659-22-076722
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220629
FILED AS OF DATE: 20220701
DATE AS OF CHANGE: 20220701
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HEALY JAMES
CENTRAL INDEX KEY: 0001245624
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38958
FILM NUMBER: 221060646
MAIL ADDRESS:
STREET 1: 3000 SAND HILL ROAD, 4-250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karuna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001771917
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270605902
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 857-449-2244
MAIL ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
tm2220245-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-06-29
0
0001771917
Karuna Therapeutics, Inc.
KRTX
0001245624
HEALY JAMES
SOFINNOVA INVESTMENTS, INC.,
3000 SAND HILL ROAD, 4-250
MENLO PARK
CA
94025
1
0
0
0
Common Stock
683
I
By Sofinnova Synergy Master Fund, LP
Common Stock
2022-06-29
4
P
0
27777
121.99
A
1980218
I
By Sofinnova Venture Partners X, LP
Common Stock
2022-06-29
4
P
0
4039
122.95
A
1984257
I
By Sofinnova Venture Partners X, LP
Common Stock
2022-06-29
4
P
0
6832
124.73
A
1991089
I
By Sofinnova Venture Partners X, LP
Common Stock
2022-06-29
4
P
0
9129
125.00
A
2000218
I
By Sofinnova Venture Partners X, LP
Common Stock
2022-06-30
4
P
0
48062
122.27
A
2048280
I
By Sofinnova Venture Partners X, LP
Common Stock
2022-06-30
4
P
0
24161
123.39
A
2072441
I
By Sofinnova Venture Partners X, LP
All shares held by Sofinnova Synergy Master Fund, LP (the "Fund"). Sofinnova Synergy Fund GP, LLC (the "GP"), the general partner of the Fund, may be deemed to have sole voting and dispositive power over these shares, and Dr. James I. Healy and Dr. Eric Delbridge, the managing members of the GP, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $121.50 to $122.00, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (2) to this Form 4.
All shares held by Sofinnova Venture Partners X, LP ("SVP X"). Sofinnova Management X, LLC (the "SM X"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $122.755 to $123.00, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $124.00 to $124.99, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $122.145 to $122.962, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $123.21 to $123.50, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (7) to this Form 4.
/s/ Nathalie Auber, Attorney-in-Fact
2022-06-30